Evidence map›Paper›PMID 36374423›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

How to Design Peptides.

Joseph Dodd-O, Amanda M Acevedo-Jake, Abdul-Rahman Azizogli, Vikram Khipple Mulligan, Vivek A Kumar

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Joseph Dodd-ODepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, USA.
Amanda M Acevedo-JakeDepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, USA.
Abdul-Rahman AzizogliDepartment of Biology, New Jersey Institute of Technology, Newark, NJ, USA.
Vikram Khipple MulliganCenter for Computational Biology, Flatiron Institute, New York, NY, USA.
Vivek A KumarYork Center for Environmental Engineering and Science, New Jersey Institute of Technology, Newark, NJ, USA. vak@njit.edu.
New Jersey Institute of Technology · USFlatiron Institute

Funding

Diversity Supplement for Angiogenic and anti-microbial supports for pulp regenerationR01DE031812 · NIDCR · UNIVERSITY OF HOUSTON · PI Vivek Kumar · 2022 to 2026
$3.3M
Peptide hydrogels for management and treatment of neovascular posterior segment diseasesR15EY029504 · NEI · NEW JERSEY INSTITUTE OF TECHNOLOGY · PI KUMAR, VIVEK · 2019 to 2020
$508k
NEI NIH HHS R15 EY029504NIDCR NIH HHS R01 DE031812
6 · The paper itself

Abstract

Novel design of proteins to target receptors for treatment or tissue augmentation has come to the fore owing to advancements in computing power, modeling frameworks, and translational successes. Shorter proteins, or peptides, can offer combinatorial synergies with dendrimer, polymer, or other peptide carriers for enhanced local signaling, which larger proteins may sterically hinder. Here, we present a generalized method for designing a novel peptide. We first show how to create a script protocol that can be used to iteratively optimize and screen novel peptide sequences for binding a target protein. We present a step-by-step introduction to utilizing file repositories, data bases, and the Rosetta software suite. RosettaScripts, an .xml interface that allows for sequential functions to be performed, is used to order the functions for repeatable performance. These strategies may lead to more groups venturing into computational design, which may result in synergies from artificial intelligence/machine learning (AI/ML) to phage display and screening. Importantly, the beginner is expected to be able to design their first peptide ligand and begin their journey in peptide drug discovery. Generally, these peptides potentially could be used to interact with any enzyme or receptor, for example, in the study of chemokines and their interactions with glycosoaminoglycans and their receptors.

Indexed as

Artificial IntelligencePeptidesLigandsProteinsSoftwareLigandsPeptidesProteinsBioactive peptidePeptide designPeptide inhibitorsPeptide ligandPeptide–protein interactionRosetta scripts

Identifiers

PMID36374423
PMCPMC11671136
OpenAlexW4308970225

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.